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Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S202Conclusions: The use of antibiotic prophylaxis in pediatric
HSCT decreased the incidence of bacteremia during trans-
plant. The use of antibacterial prophylaxis in pediatric pa-
tients undergoing HSCT should be considered, and
prospective studies are needed to conﬁrm our results.306
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Background: Multiple studies of improved glycemic control
in critically ill patients have yielded contradictory results.
Few studies on inpatient hyperglycemia exist in the BMT
population. We undertook a quality improvement project to
improve blood glucose (BG) control with a goal of increasing
the proportion of time that patients on our BMTservice spent
within the range of 70-200 mg/dl.
Methods: With the Division of Endocrinology, an algorithm
for the initiation and modiﬁcation of ﬁnger sticks and anti-
hyperglycemic medications was created and implemented
on the Tufts Medical Center BMT service for admissions
between 4/1-6/30/13 that were predicted to be > 48 hours
in duration (intervention). Using the Remote Automated
Laboratory System (RALS), the percent of time in each BG
range (<70, 71-110, 111-140, 141-199, >200) was calculated
for the entire ﬂoor in the three months prior to imple-
mentation(baseline) and during the threemonths of the pilot
program. As the oncology service is included in thiscalculation and was not part of our intervention, admissions
were analyzed for comparison. With IRB approval, retro-
spective data of admissions >48 hours was collected to
evaluate BG, length of stay, and infectious complications.
Results: The baseline cohort included 64 BMT admissions,
while there were 70 BMT admissions in the intervention
cohort and 102 oncology admissions not part of the inter-
vention. 14% of patients in each of the three admission
groups had a history of diabetes. 30% of all patients on BMT
were discharged on steroids, compared to 10% on oncology.
On admissions when ﬁnger stick evaluation of BG was
initiated (36% in the BMT intervention cohort, 25% in the
BMT baseline corhort, (P ¼ 0.25), more patients received
short acting insulin as per the algorithm (21% vs 6%, P ¼
0.016), but there was no difference in the number transi-
tioned to long acting insulin. In the intervention cohort, the
proportion of time spent in the BG range of 71-199 increased,
with less time spent with a BG < 70 or > 200 (Figure 1, P <
0.0001). Fewer BMT patients were hyperglycemic within 48
hours of a documented infection in the intervention group
compared to the baseline cohort, but the overall rate of
infection among the three groups was low. Within each
cohort on BMT, 6 admissions had a discharge BG>200, and 3
were discharged on new anti-hyperglycemic medications.
Conclusions: We were able to demonstrate the feasibility of
implementing a program to control and track blood glucose.
Not only were we able to limit hypoglycemic episodes, there
was a lower rate during the intervention compared to baseline.
The results of this retrospective study will allow the design of
larger trials to determinewhether BG control has an impact on
length of stay, infectious complications, and mortality.307
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Background: Patients undergoing allogeneic hematopoietic
stem cell transplant (HSCT) require immunosuppression to
prevent complications associated with graft versus host
disease (GVHD). Tacrolimus is used as part of combination
GVHD prophylaxis. Tacrolimus is available as an oral
formulation but is often administered as a continuous IV
infusion due to concerns of absorption and toxicity. We
report our experience substituting oral tacrolimus for IV
tacrolimus as a component of GVHD prophylaxis regimens in
patients admitted for HSCT.
Methods: We conducted a retrospective chart review of 36
patients who underwent an allogeneic HSCT and received
oral tacrolimus and 36 patients who received IV tacrolimus.
The primary endpoint was percent of tacrolimus levels in
therapeutic range. Other pertinent endpoints included theincidence of GVHD through day 100 post-transplant, increases
in serum creatinine greater than 1 mg/dL from baseline,
initiation or titration of scheduled anti-hypertensive agents,
incidence of dialysis, cost, and hospital length of stay.
Results: Groups were similar at baseline in terms of age,
gender, indication for transplantation, source of stem cells,
parenteral nutrition, and length of stay for transplant
admission. The percent of therapeutic tacrolimus levels
was similar between groups (< 10% difference in percent of
therapeutic levels, see Tacrolimus Monitoring Figures). The
number of peripheral laboratory draws was reduced from
368 to 44 draws as the majority of levels obtained while on
oral tacrolimus (n ¼ 301 levels) were drawn from existing
central lines. No difference was noted in safety endpoints
or the occurrence of acute GVHD to day +100 post-trans-
plant (See "Safety Endpoints Figure" ). Based on the
average wholesale price of tacrolimus formulations, this
change in practice resulted in a cost savings of up to
$290000.
Table 1
Patient Characteristics
Total Caphosol Cryotherapy Saline
Solution
p-value
Patients, n 117 39 40 38
Age, median
(range)
62
(39-75)
62
(45-68)
62
(39-75)
61.5
(43-70)
0.7696
Gender, n (%) 0.8962
Male 110 (94) 36 (92) 38 (95) 36 (95)
Female 7 (6) 3 (8) 2 (5) 2 (5)
Race/Ethnicity,
n (%)
0.5164
Caucasian 56 (48) 23 (59) 16 (40) 17 (45)
African
Americans
40 (34) 11 (28) 15 (37) 14 (37)
Hispanic 21 (18) 5 (13) 9 (23) 7 (18)
Karnofsky
score, n (%)
0.8394
70 1 (1) 0 (0) 1 (2.5) 0 (0)
Abstracts / Biol Blood Marrow Transplant 20 (2014) S184eS210S204Conclusion: Our institution experience with oral tacrolimus
for GVHD prophylaxis supports continuation of this practice
as a viable alternative to IV tacrolimus and results in signif-
icant cost savings.
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Background: Palifermin is a human recombinant keratino-
cyte growth factor. It was approved by the FDA in 2004
for decreasing the incidence and duration of oral mucositis
in patients receiving high dose chemotherapy and stem
cell rescue. Approval followed two randomized, placebo-
controlled, multicenter trials conducted in patients with
hematologic malignancies undergoing myeloablative condi-
tioningwith TBI. After approval, palifermin usewas extended
to non-TBI based conditioning regimens. In 2008, our insti-
tution began use of palifermin in lymphoma patients un-
dergoing BEAM conditioning and ASCT. Our goal in this study
was to assess the efﬁcacy of such a strategy in a non-TBI
based transplant group.
Methods: From 1/2008 through 6/2013 we performed 75
BEAM/ASCT on lymphoma patients using palifermin. We
compared this group to the preceding 75 lymphoma patients
who received BEAM auto-conditioning without it. The two
cohorts were compared for incidence of fever, positive blood
cultures, positive urine cultures, TPNuse, PCA use, and length
of stay (LOS). Data was collected retrospectively.
Results: Results are summarized in the table below. Of note,
there was a statistically signiﬁcant difference (p<0.05) of
fewer febrile episodes in the palifermin group and TPN use.
However there were no statistically signiﬁcant differences in
positive blood cultures, urine cultures, PCA use, or LOS.
Conclusion: Mucositis has been associated with increased
incidenceof fever. Inﬂammation rather than infectionhasbeen
postulated as themechanism formucosotis fever. Signiﬁcantly
fewer patients developed fevers in the palifermin group
though there was no difference in the incidence of positive
cultures. Palifermin reduced the use of fever workups and the
empiric use of antibiotics. TPN use was also curtailed by pal-
ifermin administration. Despite its mechanism of action of
decreasing mucositis, neither PCA use nor LOS differed sub-
stantially between the groups. It may be thatmucositis is not a
major rate-limiting step to discharge as symptoms often tend
to resolve shortly after engraftment. Further analysis
comparing time to engraftment with length of stay may helpTable
Comparison of Patient Arms (Palifermin vs. No Palifermin)
Characteristic Palifermin
(N¼75)
No Palifermin
(N¼75)
P-value
Fever 46 72 <0.05
Positive Blood Cultures 5 11 NS
Positive Urine Cultures 11 5 NS
TPN 17 58 <0.05
PCA 52 56 NS
Mean LOS 21 22 NS
Median LOS 21 21 NS
Range for LOS 12-36 12-37 N/A
NS: Not statistically signiﬁcant (using P value of <0.05)answer this question. Important future studies should include
pharmacoeconomic analysis of the relationship between pal-
ifermin, TPN antibiotics, and growth factor use as well as
overall cost and outcomes of performing BEAM/ASCTwith and
without palifermin. A CIBMTR retrospective study with addi-
tional data collection analyzing palifermin use in BEAM auto-
patients may be an expeditious way to answer many of these
questions.309
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Background: Oral mucositis (OM) is a major complication of
HDM. Previous studies analyzing the role of oral cryotherapy
(CT) in the prevention of OM are small or include patients
treated with multiple conditioning regimens.
Study Purpose: To compare the efﬁcacy of CT plus saline
solution (SS) mouth rinse vs. SS alone vs. supersaturated
calcium phosphate rinses (Caphosol) to prevent HDM-
induced OM in patients with MM undergoing
autotransplantation
Methods: One hundred and seventeen MM patients,
scheduled to receive HDM (140-200 mg/m2) followed by
autotransplantation at the Audie L. Murphy Memorial Vet-
erans Hospital in San Antonio, Texas, were randomized to the
above mentioned groups (Table 1). Patients were assessed
daily for OM until discharge or resolution of OM, using the
World Health Organization (WHO) mucositis scale. Duration80 16 (14) 6 (15) 6 (15) 4 (11)
90 100 (85) 33 (85) 33 (82.5) 7 (89)
Serum
Creatinine,
mean (SD)
1.12
(0.67)
1.28
(0.93)
1.00
(0.29)
1.09
(0.63)
0.1715
Diabetes, n (%) 0.9912
Yes 30 (26) 10 (26) 10 (25) 10 (26)
No 87 (74) 29 (74) 30 (75) 28 (74)
Dentures, n (%) 0.6336
Yes 32 (27) 9 (23) 13 (32) 10 (26)
No 85 (73) 30 (77) 27 (68) 28 (74)
Smoking, n (%) 0.9122
Yes or
history
89 (76) 30 (77) 30 (75) 29 (76)
Never 28 (24) 9 (23) 10 (25) 9 (24)
